Cryoport delivered strong third-quarter performance, achieving double-digit growth in both its Life Sciences Services and Products segments, bolstered by significant demand for cell and gene therapy support.

• Revenue from commercial cell and gene therapy surged 36% year-over-year to $8.3 million, reflecting robust market adaptation.
• Overall Life Sciences revenue rose 16% year-over-year, accounting for 55% of total revenue from continuing operations.
• The launch of next-generation cryogenic systems and new cryopreservation services positions Cryoport for further growth and market leadership.
• A new state-of-the-art global supply chain center opened in Paris enhances service capabilities in European and global markets.
• Strategic partnership with DHL Group poised to bolster market presence in the APAC and EMEA regions over time.